InflaRx N.V.IFRXEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
InflaRx N.V. is a clinical-stage biopharmaceutical company specializing in the development of novel anti-inflammatory therapies targeting the complement C5a pathway. Its pipeline addresses unmet medical needs for severe inflammatory diseases including autoimmune and rare inflammatory disorders, serving global patient populations.
Revenue
$42.6K
Gross Profit
$-2.5M
Operating Profit
N/A
Net Profit
$-15.6M
Gross Margin
-5985.4%
Operating Margin
N/A
Net Margin
-36559.8%
YoY Growth
520.3%
InflaRx N.V. Q2 FY2025 Financial Summary
InflaRx N.V. reported revenue of $42.6K (up 520.3% YoY) for Q2 FY2025, with a net profit of $-15.6M (down 4.1% YoY) (-36559.8% margin).
Key Financial Metrics
| Total Revenue | $42.6K |
|---|---|
| Net Profit | $-15.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 FY2025 |
InflaRx N.V. Quarterly Revenue & Net Profit History
InflaRx N.V. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $25.7K | — | N/A | N/A |
| Q2 FY2025 | $42.6K | +520.3% | $-15.6M | -36559.8% |
| Q2 FY2024 | $6.9K | — | $-15.0M | -217803.1% |
Income Statement
| Q2 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Revenue | $6866 | $42587 | $25736 |
| YoY Growth | N/A | 520.3% | N/A |
Balance Sheet
| Q2 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Assets | $100.5M | $79.3M | N/A |
| Liabilities | $11.8M | $17.7M | N/A |
| Equity | $88.7M | $61.6M | N/A |
Cash Flow
| Q2 2024 | Q3 2025 | |
|---|---|---|
| Operating CF | $-29.2M | $-33.1M |